Profile data is unavailable for this security.
About the company
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The Company is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The Company is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.
- Revenue in USD (TTM)0.00
- Net income in USD-147.71m
- Incorporated2019
- Employees116.00
- LocationCARGO Therapeutics Inc835 Industrial Road, Suite 400SAN CARLOS 94070United StatesUSA
- Phone+1 (650) 499-8950
- Websitehttps://cargo-tx.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics Inc | 0.00 | -142.16m | 998.94m | 85.00 | -- | 1.52 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.01bn | 300.00 | -- | 2.78 | -- | 4.89 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.03bn | 52.00 | -- | 3.37 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Praxis Precision Medicines Inc | 1.77m | -123.74m | 1.05bn | 82.00 | -- | 2.52 | -- | 595.38 | -10.26 | -10.26 | 0.1393 | 23.60 | 0.0062 | -- | -- | 21,597.56 | -43.07 | -74.04 | -46.74 | -85.12 | -- | -- | -6,987.01 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Vir Biotechnology Inc | 78.88m | -483.04m | 1.07bn | 587.00 | -- | 0.7431 | -- | 13.51 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Pharvaris NV | 0.00 | -126.85m | 1.09bn | 82.00 | -- | 2.96 | -- | -- | -2.66 | -2.66 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Travere Therapeutics Inc | 177.64m | -383.45m | 1.10bn | 380.00 | -- | 72.43 | -- | 6.18 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| AnaptysBio Inc | 30.47m | -170.12m | 1.10bn | 117.00 | -- | 101.55 | -- | 36.22 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.11bn | 116.00 | -- | 2.54 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.14bn | 50.00 | -- | 3.87 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.15bn | 452.00 | -- | -- | -- | 115.55 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -227.05m | 1.15bn | 164.00 | -- | 4.45 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Prothena Corporation PLC | 217.25m | -50.92m | 1.16bn | 173.00 | -- | 1.98 | -- | 5.32 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Day One Biopharmaceuticals Inc | 8.19m | -167.48m | 1.21bn | 169.00 | -- | 3.94 | -- | 147.73 | -1.94 | -1.94 | 0.0948 | 3.50 | 0.0193 | -- | -- | 52,851.61 | -39.35 | -- | -45.70 | -- | 91.37 | -- | -2,044.43 | -- | 4.09 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.22bn | 296.00 | -- | 6.50 | -- | 9.21 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to CARGO Therapeutics Inc's reporting currency: US Dollar USD
59.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 6.40m | 13.95% |
| RTW Investments LPas of 30 Jun 2024 | 4.08m | 8.88% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 3.68m | 8.02% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 3.12m | 6.80% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.62m | 5.70% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 1.95m | 4.24% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 1.47m | 3.20% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.43m | 3.12% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.34m | 2.91% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 1.18m | 2.58% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
